This 2010 randomized, double-blind, placebo-controlled crossover trial, published in Annals of Neurology, evaluated the impact of low-dose naltrexone (LDN) on quality of life in patients with multiple sclerosis (MS). Conducted by Cree et al. at the University of California, San Francisco, the study involved 80 participants with relapsing-remitting or secondary
